Intraperitoneal cisplatin and paclitaxel in ovarian cancer. - Wikidata - wikimedia - TriplyDB

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

http://www.wikidata.org/entity/Q53263238

about

The detection, treatment, and biology of epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Optimal primary surgical treatment for advanced epithelial ovarian cancer Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer Major clinical research advances in gynecologic cancer in 2013 The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies Evolution of management in peritoneal surface malignancies Management of relapsed ovarian cancer: a review Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy Chemotherapy of ovarian cancer in elderly patients Abdominal metastases from colorectal cancer: intraperitoneal therapy Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes Cytoreductive Surgery and HIPEC in the Baltic States: An International Scientific Workshop with Live Surgery Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer How to Create Evidence for the Integration of Local and Locoregional Treatments in Future Oncological Treatment Concepts?Ports and complications for intraperitoneal chemotherapy delivery Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review Looking up: Recent advances in understanding and treating peritoneal carcinomatosis Ovarian cancer standard of care: are there real alternatives?Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer Upper abdominal cytoreduction and thoracoscopy for advanced epithelial ovarian cancer: unanswered questions and the impact on treatment Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively?Current status and evolution of preclinical drug development models of epithelial ovarian cancer Patient preferences in advanced or recurrent ovarian cancer.Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.Advanced ovarian cancer: what should be the standard of care?The role of surgery in advanced epithelial ovarian cancer New perspectives on targeted therapy in ovarian cancer A systematic review of ovarian cancer and fear of recurrence The evolving role of catumaxomab in gastric cancer A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression Functional activation of mutant p53V172F by platinum analogs in cisplatin-resistant human tumor cells is dependent on serine-20 phosphorylation A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

P2860

Q21198791-D1CE0DD2-BE0E-4C24-A4A5-7B5320788803 Q24186509-1A64A7DF-1825-4648-9E45-9F263AF71299 Q24234923-35D780C1-3457-4C6B-A345-5716106627D1 Q24235235-47A162A9-E961-4247-8E02-3FA477BE994F Q24562146-68426841-32F2-4400-8AEA-1F7BE86A1406 Q24629295-97D8709A-AE35-470B-BF57-8734243E5AEE Q24672758-65544A83-9B57-40A3-AACD-3D0BDE6AE030 Q26738517-2ADB945F-B158-4EFA-9091-9025119CACE8 Q26741293-CD905704-80F7-452E-9BEC-90835E1705DC Q26741755-4CE838FA-AA20-4F59-AD76-10D1296C046C Q26744031-7DC73500-8B94-49F3-890A-AB174FE3C379 Q26768296-1993DF05-05C7-492C-9CDF-AC7E3AB5F9FC Q26768299-FC37D224-7080-4A80-8FFD-EABF50E1AC1C Q26768402-FF1C1890-E652-4285-913F-9866CE5BFD2F Q26771397-C2D06908-FD38-419D-8BC0-CE080976B41E Q26772268-DF0BC445-2D19-4BFB-9C47-83CE72A30A36 Q26776201-650FB6E9-57B7-4F51-B5AB-D46E30BED008 Q26780342-A0CF4376-CCAE-49B3-9E97-20071125CD58 Q26783551-83FD0A08-D132-48DD-86AA-201F95F3EEC7 Q26796520-4807F220-69A5-42ED-AD2F-39F02BA1882B Q26822458-A53BA966-7123-4A37-89F0-F5F04EA982A9 Q26828581-0652D21E-7EFF-45A6-988E-C9F39E6ADAE6 Q26849259-238C0842-79CD-4B3D-8C21-51C99D510138 Q26862249-A4BFC845-1CB7-4B4A-B8A8-C1A999DF9A86 Q27011840-FB18DE44-BD79-4EB0-92F3-69F3B3EC5D01 Q27021915-84E018CB-CE8E-494D-ACD2-7DA8896E4406 Q27024235-96D99DB3-F20B-4A36-960C-B1955463622B Q27026303-6C1DD002-83CA-48D6-AAAD-8C0D6F82F9FE Q27028117-A515CB26-C792-48F6-B35C-8755B690DD83 Q27336251-0C285424-7F53-421F-888E-712548A5A53D Q27687617-C4AB64B7-8434-4B78-93D7-9247E2CE789C Q27851688-419F4A3E-DC9B-4278-A61E-CE36A3189FF8 Q27852053-EA3E054B-0609-4574-80BE-6C6164D1E8EB Q28067698-A97451D3-64EE-40E2-A2AD-EFD68E130C7C Q28082524-D974E845-119C-4A8E-B1CC-57828FC30663 Q28087206-1D63E7B7-56EF-4BBC-B104-377AA34467FA Q28290511-FED46F94-BBF4-4386-ABAB-2DDB43018F0E Q28611264-AD66C7C9-9055-42EC-96BB-F7F0ECB01A7D Q29248201-211CCF0F-5D05-4B64-94D3-46522EA43371 Q30252871-AAEAB144-8329-4902-BB43-933B6305A9AE

P2860

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

http://www.wikidata.org/entity/Q53263238

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

@en

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

@nl

type

label

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

@en

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

@nl

prefLabel

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

@en

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

@nl

P1433

Q53263238-CC89FD77-2352-4D3F-9F3B-E2A96A3BA4B1

P1476

Q53263238-B459A605-2FEF-4DAE-B24D-D4F1B5803986

P2093

Q53263238-05775EF0-BFD5-4314-9F17-F87486D77CA5

Q53263238-2F8618B7-19EF-4364-8306-FC30434B6D99

Q53263238-3849F27F-DE51-4B1F-B77C-D34138957D3B

Q53263238-44C7CA1D-1C8B-4606-9949-BDFBAD351E63

Q53263238-44D55FE9-E724-4001-AEE7-13F78DD4EDC4

Q53263238-4D7D56EA-D6B1-441D-BE7A-476F0AEDF353

Q53263238-8FB42138-C1FF-4E4F-A226-070234E68146

Q53263238-9E297A50-CF18-43D1-B08C-C1E6826EFC86

Q53263238-AC5B2414-3A0E-4192-B3AF-0A7DC05FBBD2

Q53263238-D5709624-9645-4AD5-B7CA-4DBC4D0961DF

P304

Q53263238-8BFB7967-304E-433F-985B-87DD32E3C9DC

P31

Q53263238-200E2112-EEF1-4102-8B75-3B7CC15F7468

P356

Q53263238-B81ACE92-176E-4E87-8323-1E4362C6994A

P407

Q53263238-072D7610-193E-4628-AE98-DA99696EF24F

P433

Q53263238-9F49CA0F-1A99-46C8-8378-82749604BA1E

P478

Q53263238-3159D70C-8EED-43D1-8186-B4076E0FE590

P577

Q53263238-57455449-9D63-481B-8883-97E529DA3494

P698

Q53263238-08D7C55A-8BCC-4AAD-9484-1D1F99D43CA2

P921

Q53263238-118B1563-62D8-4D5E-A609-DE400D6F703D

P356

P1433

The New England Journal of Medicine

P1476

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

@en

P2093

Brian Bundy

http://www.w3.org/2001/XMLSchema#string

Deborah K Armstrong

http://www.w3.org/2001/XMLSchema#string

Gynecologic Oncology Group

http://www.w3.org/2001/XMLSchema#string

Helen Q Huang

http://www.w3.org/2001/XMLSchema#string

Joan L Walker

http://www.w3.org/2001/XMLSchema#string

Lari Wenzel

http://www.w3.org/2001/XMLSchema#string

Larry J Copeland

http://www.w3.org/2001/XMLSchema#string

Rebecca Baergen

http://www.w3.org/2001/XMLSchema#string

Robert A Burger

http://www.w3.org/2001/XMLSchema#string

Shashikant Lele

http://www.w3.org/2001/XMLSchema#string

P304

34-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA052985

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16394300

http://www.w3.org/2001/XMLSchema#string

P921